Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. (MLYS) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · MLYS · as of Sep 30, 2025
Ownership Breakdown
201
Institutional Holders
▲ 33 vs Q2
$3.01B
Total Inst. Value
▲ $2.12B vs Q2
66.30M
Shares Outstanding
freeFloat 69.64%
79.46M
13F Shares Held
▲ 13.77M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
MLYS largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
CATALYS PACIFIC, LLC pharmaceutical preparations | 8.90M | 13.60% | 13.60% | $337.63B | Nov 14, 2025 | — held |
RA CAPITAL MANAGEMENT, L.P. pharmaceutical preparations | 7.32M | 11.19% | 11.19% | $277.72B | Nov 14, 2025 | ▲ 1.18M |
SAMSARA BIOCAPITAL, LLC pharmaceutical preparations | 6.26M | 9.57% | 9.57% | $237.50B | Nov 14, 2025 | ▲ 588.2K |
BLACKROCK, INC. pharmaceutical preparations | 3.67M | 5.61% | 5.61% | $139.23B | Nov 12, 2025 | ▲ 573.9K |
VANGUARD GROUP INC pharmaceutical preparations | 3.02M | 4.61% | 4.61% | $114.48B | Nov 7, 2025 | ▲ 692.5K |
CALIGAN PARTNERS LP pharmaceutical preparations | 2.77M | 4.24% | 4.24% | $105.14B | Nov 14, 2025 | ▲ 755.3K |
CAPITAL INTERNATIONAL INVESTORS pharmaceutical preparations | 2.39M | 3.66% | 3.66% | $90.76B | Nov 13, 2025 | ▼ 505.6K |
SUVRETTA CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 2.13M | 3.26% | 3.26% | $80.85B | Nov 14, 2025 | ▲ 387.6K |
SR ONE CAPITAL MANAGEMENT, LP pharmaceutical preparations | 2.11M | 3.23% | 3.23% | $80.16B | Nov 12, 2025 | ▼ 1.01M |
FMR LLC pharmaceutical preparations | 2.07M | 3.16% | 3.16% | $78.54B | Nov 13, 2025 | ▲ 1.77M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
30
Increased
+14.50M shares6
New Positions
first time holders13
Decreased
−5.06M shares0
Sold Out
fully exitedNet shares change (top 50)
+9.43M
+14.50M / −5.06M
Net new holders
+23
6 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
MLYS insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
10
Buy transactions
19
Sell transactions
0.53
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Rodman David Malcom Chief Medical Officer | May 18, 2026 | Sale | 417 | $27.55 | $11.5K | 63.4K | Form 4 ↗ |
Rodman David Malcom Chief Medical Officer | May 12, 2026 | Sale | 6,348 | $29.36 | $186.3K | 69.8K | Form 4 ↗ |
Rodman David Malcom Chief Medical Officer | May 11, 2026 | Sale | 2,171 | $29.71 | $64.5K | 69.8K | Form 4 ↗ |
Rodman David Malcom Chief Medical Officer | May 13, 2026 | Sale | 14,056 | $28.58 | $401.8K | 63.4K | Form 4 ↗ |
Rodman David Malcom Chief Medical Officer | Apr 17, 2026 | Sale | 416 | $31.33 | $13.0K | 69.8K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Mineralys Therapeutics, Inc. (MLYS) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 30.36%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Mineralys Therapeutics, Inc. is CATALYS PACIFIC, LLC, holding approximately 8.90 million shares — equal to 13.60% of outstanding shares — as of September 30, 2025.
A total of 201 institutional investors currently hold MLYS stock, with a combined institutional value of approximately $3.01 billion as of the most recent 13F filing period.
Frequently asked questions
MLYS ownershipMineralys Therapeutics, Inc. (MLYS) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is CATALYS PACIFIC, LLC with a 13.60% stake. Company insiders hold 30.36%. Data sourced from SEC Form 13F as of September 30, 2025.